⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 17, 2024

Supplementary Figure 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma

View Full Paper

Ask AI

Bookmark

Share

Abstract

This figure entails the selection of HNSCC and LUSC PDX model based on the H-score of EGFR and MET.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lim et al. (2024) studied this question.

synapsesocial.com/papers/68e60020b6db6435875941e9 https://doi.org/10.1158/2767-9764.26318628

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024
2Supplementary Figure 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024
3Supplementary Figure 1 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024
4Supplementary Figure 4 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024
5Supplementary Figure 4 from Exploration of Immune-Modulatory Effects of Amivantamab in Combination with Pembrolizumab in Lung and Head and Neck Squamous Cell Carcinoma2024